We therefore asked whether MYCN-amplified cells are more sensitive to methotrexate than those without MYCN amplification by generating dose-response data for a panel of 13 neuroblastoma cell lines, 7 of which were MYCN-amplified and 6 single copy. The gene discussed is MYCN; the disease is neuroblastoma.